Prognostic performance of copeptin among patients with acute decompensated heart failure.

Autor:	Ozmen C; Faculty of Medicine, Department of Cardiology, Cukurova University, Adana, Turkey., Deveci OS; Faculty of Medicine, Department of Cardiology, Cukurova University, Adana, Turkey., Tepe O; Faculty of Medicine, Department of Cardiology, Cukurova University, Adana, Turkey., Yesildas C; Faculty of Medicine, Department of Cardiology, Mersin University, Mersin, Turkey., Ünal İ; Faculty of Medicine, Department of Biostatistics, Cukurova University, Adana, Turkey., Yıldız İ; Department of Cardiology, Osmaniye State Hospital, Osmaniye, Turkey., Eker Akıllı R; Faculty of Medicine, Department of Cardiology, Cukurova University, Adana, Turkey., Deniz A; Faculty of Medicine, Department of Cardiology, Cukurova University, Adana, Turkey., Demir M; Faculty of Medicine, Department of Cardiology, Cukurova University, Adana, Turkey., Kanadaşı M; Faculty of Medicine, Department of Cardiology, Cukurova University, Adana, Turkey., Usal A; Faculty of Medicine, Department of Cardiology, Cukurova University, Adana, Turkey.
Jazyk:	angličtina
Zdroj:	Acta cardiologica [Acta Cardiol] 2021 Oct; Vol. 76 (8), pp. 842-851. Date of Electronic Publication: 2020 Jul 15.
DOI:	10.1080/00015385.2020.1786624
Abstrakt:	Background: In heart failure (HF), various biomarkers have been established for prognosis. However, little is known about the relevance of copeptin measurements to HF. This study aimed to explore the prognostic value of copeptin for predicting cardiovascular (CV) death or HF-related re-hospitalisation in patients with acute decompensated HF. Materials and Methods: We prospectively enrolled 155 consecutive patients with acute signs and symptoms of HF. Plasma copeptin and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels were measured at admission. Patients were monitored for 90 days regarding the composite endpoint of CV death or acute HF-related re-hospitalisation. Results: Of the 155 patients enrolled, 40 reached the endpoint, and 115 were in a stable condition during follow-up. Patients who reached an adverse endpoint showed higher NT-proBNP and copeptin levels compared to patients in stable condition. Receiver operating characteristic curve analysis revealed that the area under curve of copeptin 0.844 (95% CI, 0.753-0.935) was superior to that of NT-proBNP 0.809 (95% CI, 0.729-0.890) for the prediction of adverse events within 90 days. Meanwhile, compared to the group with lower copeptin levels (<34 pmol/L), patients with higher copeptin levels (≥34 pmol/L) were at a 10.672-times higher risk of CV death or acute HF-related re-hospitalisation. Multivariate Cox proportional hazards regression analysis revealed that increased copeptin level was a significantly independent predictor of adverse events (risk ratio, 1.051; 95% CI, 1.020-1.083; p  < 0.001). Conclusion: Copeptin was found to be a strong, novel marker for predicting CV death or HF-related re-hospitalisation in patients with acute decompensated HF.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu